Malaria drug discovery has shifted from a focus on targeting asexual blood stage parasites, to the development of drugs that can also target exo-erythrocytic forms and/or gametocytes in order to prevent malaria and/or parasite transmission. In this work, we aimed to develop parasite-selective histone deacetylase inhibitors (HDACi) with activity against the disease-causing asexual blood stages of Plasmodium malaria parasites as well as with causal prophylactic and/or transmission blocking properties. An optimized one-pot, multi-component protocol via a sequential Ugi four-component reaction and hydroxylaminolysis was used for the preparation of a panel of peptoid-based HDACi. Several compounds displayed potent activity against drug-sensitive and drug-resistant P. falciparum asexual blood stages, high parasite-selectivity and submicromolar activity against exo-erythrocytic forms of P. berghei. Our optimization study resulted in the discovery of the hit compound 1u which combines high activity against asexual blood stage parasites (Pf 3D7 IC: 4 nM; Pf Dd2 IC: 1 nM) and P. berghei exo-erythrocytic forms (Pb EEF IC: 25 nM) with promising parasite-specific activity (SI: 2496, SI: 9990, and SI: 400).
Malaria, caused by Plasmodium parasites,
results in >400,000 deaths annually. There is no effective vaccine,
and new drugs with novel modes of action are needed because of increasing
parasite resistance to current antimalarials. Histone deacetylases
(HDACs) are epigenetic regulatory enzymes that catalyze post-translational
protein deacetylation and are promising malaria drug targets. Here,
we describe quantitative structure–activity relationship models
to predict the antiplasmodial activity of hydroxamate-based HDAC inhibitors.
The models incorporate P. falciparum in vitro activity data for 385 compounds containing a hydroxamic
acid and were subject to internal and external validation. When used
to screen 22 new hydroxamate-based HDAC inhibitors for antiplasmodial
activity, model A7 (external accuracy 91%) identified
three hits that were subsequently verified as having potent in vitro
activity against P. falciparum parasites
(IC50 = 6, 71, and 84 nM), with 8 to 51-fold selectivity
for P. falciparum versus human cells.
The prevention and treatment of malaria requires a multi-pronged approach, including the development of drugs that have novel modes of action. Histone deacetylases (HDACs), enzymes involved in post-translational protein modification, are potential new drug targets for malaria. However, the lack of recombinant
P. falciparum
HDACs and suitable activity assays, has made the investigation of compounds designed to target these enzymes challenging. Current approaches are indirect and include assessing total deacetylase activity and protein hyperacetylation via Western blot. These approaches either do not allow differential compound effects to be determined or suffer from low throughput. Here we investigated dot blot and ELISA methods as new, higher throughput assays to detect histone lysine acetylation changes in
P. falciparum
parasites. As the ELISA method was found to be superior to the dot blot assay using the control HDAC inhibitor vorinostat, it was used to evaluate the histone H3 and H4 lysine acetylation changes mediated by a panel of six HDAC inhibitors that were shown to inhibit
P. falciparum
deacetylase activity. Vorinostat, panobinostat, trichostatin A, romidepsin and entinostat all caused an ~3-fold increase in histone H4 acetylation using a tetra-acetyl lysine antibody. Tubastatin A, the only human HDAC6-specific inhibitor tested, also caused H4 hyperacetylation, but to a lesser extent than the other compounds. Further investigation revealed that all compounds, except tubastatin A, caused hyperacetylation of the individual N-terminal H4 lysines 5, 8, 12 and 16. These data indicate that tubastatin A impacts
P. falciparum
H4 acetylation differently to the other HDAC inhibitors tested. In contrast, all compounds caused hyperacetylation of histone H3. In summary, the ELISA developed in this study provides a higher throughput approach to assessing differential effects of antiplasmodial compounds on histone acetylation levels and is therefore a useful new tool in the investigation of HDAC inhibitors for malaria.
The Front Cover illustrates hit compound 2h which is active on Plasmodium falciparum‐infected erythrocytes. A homology model of the putative P. falciparum histone deacetylase (HDAC) molecular target is shown in gold. The neglected disease malaria is responsible for over 400,000 deaths each year, and P. falciparum is the most lethal of the human malaria parasites. Parasite resistance has been reported for all currently used antimalarial drugs, and new drugs are needed. In this work we present peptoid‐based HDAC inhibitors as novel compounds with potent dual‐stage antiplasmodial activity. Cover artwork by M. K. W. Mackwitz and E. Hesping. More information can be found in the Full Paper by Finn K. Hansen, Katherine T. Andrews et al. on page 912 in Issue 9, 2019 (DOI: 10.1002/cmdc.201800808).
Malaria parasites are transmitted by mosquitoes and a substantial part of the parasite's complex life cycle takes place inside the insect. Parasite transmission starts with the uptake of parasite stages called gametocytes from the vertebrate host with the blood meal of a female vector mosquito, completing several weeks later with the injection of parasite stages called sporozoites into the vertebrate host by mosquito bite. The sporozoites form in their thousands inside ookinete‐derived oocysts situated on the abluminal side of the mosquito midgut epithelium by a process of cell division known as sporogony. After their formation, sporozoites egress from the oocyst into the haemolymph, invade the salivary glands and mature to become infective to the vertebrate. This MicroCommentary reviews recent reports describing a conserved plasma membrane‐associated protein of Plasmodium berghei, PBANKA_1422900, and its role in maintaining the shape and structural integrity of sporozoites in salivary glands and during inoculation into the vertebrate host. Combined results from three separate studies provide mechanistic insights into how this protein achieves structural maintenance of the sporozoite, and how in turn this promotes the sporozoite's ability to overcome several physical obstacles and allow it to establish infection in the vertebrate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.